Sponsor

Rahul Aggarwal

Clinical research sponsor

Published trials13

Recruiting shown2

Roles1

SourceClinicalTrials.gov

Clinical trials

13 shown

Imaging of Solid Tumors Using 18F-TRXNCT06942104 · lead sponsor · 2025-07-03

RECRUITING

64Cu-GRIP B in Patients With Advanced MalignanciesNCT05888532 · lead sponsor · 2023-05-25

RECRUITING

Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate CancerNCT04926181 · lead sponsor · 2022-03-16

TERMINATED

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate CancerNCT05011188 · lead sponsor · 2022-01-19

ACTIVE_NOT_RECRUITING

11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor ExpressionNCT04927663 · lead sponsor · 2021-08-10

TERMINATED

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate CancerNCT04471974 · lead sponsor · 2021-01-26

ACTIVE_NOT_RECRUITING

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid TumorsNCT03682289 · lead sponsor · 2019-01-17

ACTIVE_NOT_RECRUITING

Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor MalignanciesNCT03590054 · lead sponsor · 2018-08-20

COMPLETED

Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant Prostate CancerNCT02911467 · lead sponsor · 2016-11-08

TERMINATED

Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor MalignanciesNCT02913131 · lead sponsor · 2016-10-20

TERMINATED

LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPCNCT02494921 · lead sponsor · 2015-11-20

COMPLETED

Gallium-68 Citrate PET Used in Prostate CancerNCT02391025 · lead sponsor · 2015-05-28

COMPLETED

Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate CancerNCT01594918 · lead sponsor · 2012-06-01

COMPLETED

Sponsor roles

lead sponsor13

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.